Mark Schoenfisch

Mark Schoenfisch

Peter A. Ornstein Distinguished Professor, Jointly appointed with the School of Medicine & School of Pharmacy

   Caudill Laboratories 336
  Group Website
  Curriculum Vitae

Research Interests

Analytical Sensors, Biomaterials & Nanoparticle Therapeutics

Research Synopsis

Our research is focused on four main areas: 1) designing macromolecular nitric oxide release vehicles as novel therapeutics; 2) improving the analytical performance of implantable continuous glucose monitoring devices for diabetes management; 3) designing microfluidic nitric oxide, NO, sensors for real-time detection of NO in biological media; and, 4) developing superhydrophobic interfaces for mold prevention and remediation.
In the Schoenfisch Lab, we work at the interface of analytical chemistry, materials science, biomedical engineering, and biology. The types of multi-disciplinary research opportunities that are available include studies of therapeutics to treat various diseases; sensors that function reliably and continuously, real time, to facilitate disease management; microelectrode and microfluidic sensor design and fabrication for clinical, point-of-care, and diagnostic/prognostic applications; and, new macromolecular scaffolds that manipulate biology and physiology.

Professional Background

University of Kansas, B.A., 1992; University of Arizona, Ph.D., 1997; University of Michigan, National Institutes of Health Postdoctoral Fellow, 1998-1999; Society for Analytical Chemists of Pittsburgh Young Investigator Award, 2001; Eli Lilly and Company Young Investigator Award, 2002-2004; National Science Foundation CAREER Award, 2004-2009; International Union of Pure and Applied Chemistry Young Observer Award , 2005; John L. Sanders Award for Excellence in Undergraduate Teaching and Service, 2007; Chapman Family Teaching Award for Distinguished Teaching of Undergraduate Students, 2015

News & Publications

Our research group has developed nitric oxide-releasing biopolymers as alternatives to conventional antibiotics. Here, we show that nitric oxide acts as a broad-spectrum antibacterial agent while also improving the efficacy of conventional antibiotics when delivered sequentially.


Pseudomonas aeruginosa is the main contributor to the morbidity and mortality of cystic fibrosis (CF) patients. Nitric oxide (NO) can both disrupt the physical structure of the biofilm and eradicate interior colonies. The effects of a CF-like growth environment on P. aeruginosa biofilm susceptibility to NO were investigated using parallel plate macrorheology and particle tracking microrheology.